{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-036430","form_type":"8-K","ticker":"AVR","cik":"0002011514","company_name":"Anteris Technologies Global Corp.","filed_at":"2025-09-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.810024+00:00","generated_at":"2026-05-17T05:27:52.498382+00:00","sec_items":["5.07","8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Anteris delays PARADIGM pivotal trial enrollment to Q4 2025 after FDA request","bullets":["Patient enrollment in PARADIGM trial now expected Q4 2025, previously Q3 2025.","FDA requested additional bench testing info; company submitted formal response to IDE.","Regulatory submissions to European authorities are underway for multi-regional trial.","Stockholders approved ASX waiver proposal (13.66M for, 2.60M against) at Sept 29 special meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-036430","json":"https://secwatch.observer/filing/0001140361-25-036430.json","markdown":"https://secwatch.observer/filing/0001140361-25-036430.md","text":"https://secwatch.observer/filing/0001140361-25-036430.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2011514/000114036125036430/0001140361-25-036430-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2011514/000114036125036430/ef20054947_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:27:52.498382+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}